Trastuzumab continues to show life for HER2-positve early stage breast cancer

October 20, 2014 10:04 PM

1 0

JACKSONVILLE, Fla. — After following breast cancer patients for an average of eight-plus years, researchers say that adding trastuzumab (Herceptin) to chemotherapy significantly improved the overall and disease-free survival of women with early stage HER2-positive breast cancer.

They found that the use of trastuzumab produced a 37 percent improvement in survival and a 40 percent reduction in risk of cancer occurrence, compared to patients treated with chemotherapy alone.

Also read: RBS Fails Toughest-Ever BOE Stress Test, Boosts Capital Plan

Read more

To category page

Loading...